Suppr超能文献

他莫昔芬辅助治疗及低脂饮食对绝经后乳腺癌患者血清结合蛋白及雌二醇生物利用度的影响。

Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients.

作者信息

Rose D P, Chlebowski R T, Connolly J M, Jones L A, Wynder E L

机构信息

American Health Foundation, Valhalla, New York 10595.

出版信息

Cancer Res. 1992 Oct 1;52(19):5386-90.

PMID:1394142
Abstract

Serum was collected at intervals from postmenopausal breast cancer patients to determine the effects of tamoxifen adjuvant therapy and a low-fat dietary intervention, alone and in combination, on sex hormone-binding globulin (SHBG) concentrations and circulating estradiol bioavailability. Serum corticosteroid-binding globulin and follicle-stimulating hormone were also assayed as indicators of patient compliance to tamoxifen therapy. The immunoreactive SHBG concentration was higher (P less than 0.001) in 22 patients who had been treated with tamoxifen for 6-36 weeks when first sampled, compared with 27 who were not receiving tamoxifen therapy. Tamoxifen also produced a reduction in the percentage non-protein-bound estradiol (P less than 0.001) and percentage albumin-bound estradiol (P less than 0.01), the two biologically available fractions, and a corresponding increase in the percentage SHBG-bound estradiol (P less than 0.01). A longitudinal study of 7 patients showed significant reductions in the percentage of albumin-bound estradiol and an increased percentage of SHBG-bound estradiol, after 3-6 months of tamoxifen; after 12-18 months there was also a significant decrease in the non-protein-bound estradiol fraction. We conclude that in postmenopausal breast cancer patients the redistribution of circulating estradiol, with reduced bioavailability, provides an additional mechanism to those demonstrated previously for the therapeutic activity of tamoxifen. Another 12 patients receiving tamoxifen and 8 who were not were followed for 6-12 months on a low-fat diet (fat comprised 20% of the total calories). The dietary intervention had no effect on the serum SHBG concentration or the estradiol distribution. Although tamoxifen increased the serum corticosteroid-binding globulin and partially suppressed the follicle-stimulating hormone concentrations, the responses obtained were less consistent compared with those of the SHBG levels.

摘要

从绝经后乳腺癌患者中定期采集血清,以确定他莫昔芬辅助治疗和低脂饮食干预单独及联合应用对性激素结合球蛋白(SHBG)浓度和循环雌二醇生物利用度的影响。还检测血清皮质类固醇结合球蛋白和促卵泡激素,作为患者对他莫昔芬治疗依从性的指标。首次采样时,22例接受他莫昔芬治疗6 - 36周的患者,其免疫反应性SHBG浓度高于27例未接受他莫昔芬治疗的患者(P < 0.001)。他莫昔芬还使两种生物可利用部分,即非蛋白结合雌二醇百分比(P < 0.001)和白蛋白结合雌二醇百分比(P < 0.01)降低,而SHBG结合雌二醇百分比相应增加(P < 0.01)。对7例患者的纵向研究表明,他莫昔芬治疗3 - 6个月后,白蛋白结合雌二醇百分比显著降低,SHBG结合雌二醇百分比增加;12 - 18个月后,非蛋白结合雌二醇部分也显著下降。我们得出结论,在绝经后乳腺癌患者中,循环雌二醇的重新分布及生物利用度降低,为他莫昔芬的治疗活性提供了一种先前已证明之外的额外机制。另外12例接受他莫昔芬治疗的患者和8例未接受治疗的患者,进行了6 - 12个月的低脂饮食(脂肪占总热量的20%)随访。饮食干预对血清SHBG浓度或雌二醇分布无影响。虽然他莫昔芬增加了血清皮质类固醇结合球蛋白并部分抑制了促卵泡激素浓度,但与SHBG水平相比,所获得的反应不太一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验